BIOMARIN PHARMACEUTICAL INC OCI, before Reclassifications, before Tax, Attributable to Parent
BIOMARIN PHARMACEUTICAL INC (BMRN) reported OCI, before Reclassifications, before Tax, Attributable to Parent of -$8.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC oci, before reclassifications, before tax, attributable to parent for the quarter ending 2026-06-30 was -$8.60M.
- BIOMARIN PHARMACEUTICAL INC oci, before reclassifications, before tax, attributable to parent for the quarter ending 2026-03-31 was -$699.00K.
- BIOMARIN PHARMACEUTICAL INC oci, before reclassifications, before tax, attributable to parent for the quarter ending 2025-12-31 was $3.73M, a 94.21% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC oci, before reclassifications, before tax, attributable to parent for the quarter ending 2025-09-30 was $2.65M.
- BIOMARIN PHARMACEUTICAL INC oci, before reclassifications, before tax, attributable to parent for fiscal 2025 was -$90.01M, a 185.24% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC oci, before reclassifications, before tax, attributable to parent for fiscal 2024 was $105.60M.
- BIOMARIN PHARMACEUTICAL INC oci, before reclassifications, before tax, attributable to parent for fiscal 2023 was -$20.84M, a 238.18% decline from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC oci, before reclassifications, before tax, attributable to parent for fiscal 2022 was $15.08M, a 45.21% decline from fiscal 2021.
| Period end | OCI, before Reclassifications, before Tax, Attributable to Parent 3 month | OCI, before Reclassifications, before Tax, Attributable to Parent 6 month | OCI, before Reclassifications, before Tax, Attributable to Parent 9 month | OCI, before Reclassifications, before Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.60M 10-Q · filed 2026-08-06 | -$9.30M 10-Q · filed 2026-08-06 | -$5.57M derived: sum of 3 quarters · filed 2026-08-06 | -$2.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$699.00K 10-Q · filed 2026-05-05 | $3.03M derived: sum of 2 quarters · filed 2026-05-05 | $5.68M derived: sum of 3 quarters · filed 2026-05-05 | -$58.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.38M derived: sum of 2 quarters · filed 2026-02-26 | -$57.80M derived: sum of 3 quarters · filed 2026-08-06 | -$90.01M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.65M 10-Q · filed 2025-10-28 | -$61.52M derived: sum of 2 quarters · filed 2026-08-06 | -$93.74M 10-Q · filed 2025-10-28 | -$29.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$64.17M 10-Q · filed 2026-08-06 | -$96.39M 10-Q · filed 2026-08-06 | -$31.93M derived: sum of 3 quarters · filed 2026-08-06 | -$48.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$32.22M 10-Q · filed 2026-05-05 | $32.25M derived: sum of 2 quarters · filed 2026-05-05 | $15.90M derived: sum of 3 quarters · filed 2026-05-05 | $46.77M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $64.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $48.12M derived: sum of 2 quarters · filed 2026-02-26 | $78.98M derived: sum of 3 quarters · filed 2026-02-26 | $105.60M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$16.35M 10-Q · filed 2025-10-28 | $14.52M derived: sum of 2 quarters · filed 2025-10-28 | $41.14M 10-Q · filed 2025-10-28 | $8.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $30.87M 10-Q · filed 2025-08-05 | $57.48M 10-Q · filed 2025-08-05 | $25.13M derived: sum of 3 quarters · filed 2026-02-26 | $46.66M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $26.62M 10-Q · filed 2025-05-02 | -$5.73M derived: sum of 2 quarters · filed 2026-02-26 | $15.79M derived: sum of 3 quarters · filed 2026-02-26 | $8.39M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$32.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$10.82M derived: sum of 2 quarters · filed 2026-02-26 | -$18.22M derived: sum of 3 quarters · filed 2026-02-26 | -$20.84M 10-K · filed 2026-02-26 |
| 2023-09-30 | $21.53M 10-Q · filed 2024-10-31 | $14.13M derived: sum of 2 quarters · filed 2024-10-31 | $11.52M 10-Q · filed 2024-10-31 | -$5.23M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | -$7.40M 10-Q · filed 2024-08-05 | -$10.01M 10-Q · filed 2024-08-05 | -$26.75M derived: sum of 3 quarters · filed 2025-02-24 | -$4.07M derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | -$2.61M 10-Q · filed 2024-04-26 | -$19.36M derived: sum of 2 quarters · filed 2025-02-24 | $3.33M derived: sum of 3 quarters · filed 2025-02-24 | $25.96M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | -$16.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $5.94M derived: sum of 2 quarters · filed 2025-02-24 | $28.58M derived: sum of 3 quarters · filed 2025-02-24 | $15.08M 10-K · filed 2025-02-24 |
| 2022-09-30 | $22.69M 10-Q · filed 2023-11-02 | $45.32M derived: sum of 2 quarters · filed 2023-11-02 | $31.82M 10-Q · filed 2023-11-02 | $38.72M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $22.64M 10-Q · filed 2023-08-02 | $9.14M 10-Q · filed 2023-08-02 | $16.03M derived: sum of 3 quarters · filed 2024-02-26 | $27.16M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$13.50M 10-Q · filed 2023-04-28 | -$6.60M derived: sum of 2 quarters · filed 2024-02-26 | $4.52M derived: sum of 3 quarters · filed 2024-02-26 | -$3.93M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $18.02M derived: sum of 2 quarters · filed 2024-02-26 | $9.57M derived: sum of 3 quarters · filed 2024-02-26 | $27.52M 10-K · filed 2024-02-26 |
| 2021-09-30 | $11.13M 10-Q · filed 2022-10-28 | $2.68M derived: sum of 2 quarters · filed 2022-10-28 | $20.63M 10-Q · filed 2022-10-28 | -$5.64M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$8.45M 10-Q · filed 2022-08-04 | $9.50M 10-Q · filed 2022-08-04 | -$16.77M derived: sum of 3 quarters · filed 2023-02-27 | -$35.07M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $17.95M 10-Q · filed 2022-04-29 | -$8.32M derived: sum of 2 quarters · filed 2023-02-27 | -$26.62M derived: sum of 3 quarters · filed 2023-02-27 | -$22.83M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$26.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$44.56M derived: sum of 2 quarters · filed 2023-02-27 | -$40.78M derived: sum of 3 quarters · filed 2023-02-27 | -$22.47M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$18.30M 10-Q · filed 2021-10-29 | -$14.51M derived: sum of 2 quarters · filed 2021-10-29 | $3.80M 10-Q · filed 2021-10-29 | -$6.50M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $3.78M 10-Q · filed 2021-07-30 | $22.09M 10-Q · filed 2021-07-30 | $11.79M derived: sum of 3 quarters · filed 2022-02-25 | $36.29M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $18.31M 10-Q · filed 2021-04-30 | $8.01M derived: sum of 2 quarters · filed 2022-02-25 | $32.51M derived: sum of 3 quarters · filed 2022-02-25 | $34.42M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $14.19M derived: sum of 2 quarters · filed 2022-02-25 | $16.11M derived: sum of 3 quarters · filed 2022-02-25 | $32.39M 10-K · filed 2022-02-25 |
| 2019-09-30 | $24.49M 10-Q · filed 2020-11-06 | $26.41M derived: sum of 2 quarters · filed 2020-11-06 | $42.68M 10-Q · filed 2020-11-06 | $51.18M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $1.91M 10-Q · filed 2020-08-05 | $18.19M 10-Q · filed 2020-08-05 | $26.68M derived: sum of 3 quarters · filed 2021-02-26 | $31.51M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $16.28M 10-Q · filed 2020-05-01 | $24.77M derived: sum of 2 quarters · filed 2021-02-26 | $29.60M derived: sum of 3 quarters · filed 2021-02-26 | $54.71M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $8.49M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $13.32M derived: sum of 2 quarters · filed 2021-02-26 | $38.43M derived: sum of 3 quarters · filed 2021-02-26 | $27.18M 10-K · filed 2021-02-26 |
| 2018-09-30 | $4.83M 10-Q/A · filed 2019-11-04 | $29.94M derived: sum of 2 quarters · filed 2019-11-04 | $18.69M 10-Q/A · filed 2019-11-04 | $11.54M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $25.11M 10-Q · filed 2019-08-02 | $13.86M 10-Q · filed 2019-08-02 | $6.71M derived: sum of 3 quarters · filed 2019-08-02 | -$3.71M derived: sum of 4 quarters · filed 2019-08-02 |
| 2018-03-31 | -$11.25M 10-Q · filed 2019-04-29 | -$18.40M derived: sum of 2 quarters · filed 2019-04-29 | -$28.82M derived: sum of 3 quarters · filed 2019-04-29 | -$47.71M derived: sum of 4 quarters · filed 2019-04-29 |
| 2017-12-31 | -$7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | -$17.57M derived: sum of 2 quarters · filed 2019-02-28 | -$36.47M derived: sum of 3 quarters · filed 2019-02-28 | -$39.10M 10-K · filed 2019-02-28 |
| 2017-09-30 | -$10.42M 10-Q · filed 2018-10-26 | -$29.31M derived: sum of 2 quarters · filed 2018-10-26 | -$31.95M 10-Q · filed 2018-10-26 | -$20.04M derived: sum of 4 quarters · filed 2018-10-26 |
| 2017-06-30 | -$18.89M 10-Q · filed 2018-08-03 | -$21.53M 10-Q · filed 2018-08-03 | -$9.62M derived: sum of 3 quarters · filed 2018-08-03 | -$9.87M derived: sum of 4 quarters · filed 2018-08-03 |
| 2017-03-31 | -$2.63M 10-Q · filed 2018-04-27 | $9.27M derived: sum of 2 quarters · filed 2018-04-27 | $9.02M derived: sum of 3 quarters · filed 2018-04-27 | $11.10M derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | $11.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $11.66M derived: sum of 2 quarters · filed 2018-02-26 | $13.73M derived: sum of 3 quarters · filed 2018-02-26 | -$2.43M 10-K · filed 2018-02-26 |
| 2016-09-30 | -$247.00K 10-Q · filed 2017-10-31 | $1.82M derived: sum of 2 quarters · filed 2017-10-31 | -$14.33M 10-Q · filed 2017-10-31 | -$16.61M derived: sum of 4 quarters · filed 2017-10-31 |
| 2016-06-30 | $2.07M 10-Q · filed 2017-08-02 | -$14.09M 10-Q · filed 2017-08-02 | -$16.36M derived: sum of 3 quarters · filed 2017-08-02 | -$21.39M derived: sum of 4 quarters · filed 2017-08-02 |
| 2016-03-31 | -$16.16M 10-Q · filed 2017-05-04 | -$18.43M derived: sum of 2 quarters · filed 2017-05-04 | -$23.47M derived: sum of 3 quarters · filed 2017-05-04 | |
| 2015-12-31 | -$2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$7.31M derived: sum of 2 quarters · filed 2017-02-27 | $12.78M 10-K · filed 2017-02-27 | |
| 2015-09-30 | -$5.03M 10-Q · filed 2016-11-03 | $15.06M 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |